Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.
about
Management of antipsychotic-related weight gainA double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)STEPWISE - STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trial.MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health AdministrationThe potential role of appetite in predicting weight changes during treatment with olanzapine.Pharmacovigilance on olanzapine.Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.Almost all antipsychotics result in weight gain: a meta-analysis.The effects of atypical antipsychotic usage duration on serum adiponectin levels and other metabolic parameters.Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.Olanzapine: a critical review of recent literature.Weight change with atypical antipsychotics in the treatment of schizophrenia.The role of lifestyle interventions and weight management in schizophrenia.Current schizophrenia drugs: efficacy and side effects.The orexins/hypocretins and schizophreniaEarly evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorderDouble-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complicationsSchizophrenia, obesity, and antipsychotic medications: what can we do?Factors associated with response to clozapine in schizophrenia: a review.Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow upWeight gain associated with taking psychotropic medication: an integrative review.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Changes in BMI in hospitalized patients during treatment with antipsychotics, depending on gender and other factors.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study.Metabolic Syndrome Screening and Assertive Community Treatment: A Quality Improvement Study.Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia.An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.
P2860
Q24610124-CB2B9DB7-8E0A-4516-9653-26CD8752A668Q24624661-71459E15-464A-4AB8-B9E6-CB660D8480B8Q27331464-02061F4C-CF81-403D-8199-F50556C59011Q28296094-E70270F9-63D1-46EE-B835-2ECD8E0E5D44Q33257886-8921B4C9-89E3-4682-AF16-8B5C8BDC492EQ33423275-0D36A138-92D2-4D45-A7E6-D0EB9C88C999Q33519730-925A91CA-569F-402C-A71D-37428073EBE1Q33692484-E4544BD6-0A2A-4572-97FF-F6B2EFEEA561Q34138231-417A94EC-ED78-458C-85C4-0F7013506FBBQ34213209-3D81D709-F9D5-470E-BAEF-1A589EC608D9Q34330761-672D217E-BA32-41AE-B8BA-5B0559C2E063Q34661499-9E2B80E0-077B-49D8-A264-796B36AF1D9AQ34666581-E77CEBBC-6552-4121-AACF-083AE3127D53Q35566102-9AA1B6EE-22D3-490F-B069-13FAB60EC3AAQ35652340-BA0913A1-DBDD-431E-9FB2-D3C507A2ADAFQ36061639-371F81A3-EFD9-461F-B889-9D33840EF60AQ36273449-FF583DA0-BD2E-4AFE-BC0D-58B0806A10A4Q36310286-68EEC349-B27C-4DE7-8C1E-29163CF68AACQ36310289-C3DFBB9A-AF7C-4A94-874F-90AE06B86FA7Q36488206-63BABBF2-8A59-4F30-8D61-38BB31842024Q36922767-72B95BBC-3FA9-4949-833B-BED574378423Q36934711-1C1CA859-8510-43FD-8E45-E19B5644FE1EQ37052769-270A9C3E-E3E5-446D-8220-E09F29A1357EQ37220366-B83E0D18-724F-4BA4-B14B-B41ECE42D391Q37226376-E01091AA-C9DA-4974-8C6C-00549F5D9B2BQ37300007-A3566652-C094-4478-82B2-D1F4BF60FA5CQ37494988-F56323DA-7CBD-4777-B4F3-C3FCA16257BDQ37865068-5CC0CD15-DE6F-42BA-B232-86F13D4996D8Q37865505-76115F91-8541-4E59-BC18-1392BF17EF41Q37963571-B5C64F04-3AF7-4215-8410-51141F324BF7Q38132709-92A05106-083D-43BC-8BFD-247CE8956B6FQ38504254-0FC6BBC9-37DA-46F3-81FE-E6881DDFD499Q38789687-12F4FD72-7B2B-4CB9-B67B-2C3C254487E5Q38826206-DB2745A9-3FDC-4818-9100-C22420AC3541Q38838191-F8D7BBB0-2C45-47FE-AC1B-7FD5EA2839A2Q40306195-9C73E152-1BBD-4CB9-95B1-32CB946292FCQ42433433-496CD7F1-8350-4D7E-86A3-0792D2128AEDQ42905755-445FD5A0-9CBB-4C19-A77B-A7082E6DD244Q45928108-89FA4A93-B71D-47B7-AD8E-EBD28274D9ABQ46708448-709DEC7D-7B65-42AC-B12C-0048567FFFD6
P2860
Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Association between early and ...... phrenia and related disorders.
@en
Association between early and ...... phrenia and related disorders.
@nl
type
label
Association between early and ...... phrenia and related disorders.
@en
Association between early and ...... phrenia and related disorders.
@nl
prefLabel
Association between early and ...... phrenia and related disorders.
@en
Association between early and ...... phrenia and related disorders.
@nl
P2093
P921
P1476
Association between early and ...... phrenia and related disorders.
@en
P2093
Bruce J Kinon
Christopher J Kaiser
Matthew D Rotelli
Saeed Ahmed
Sara Kollack-Walker
P304
P356
10.1097/01.JCP.0000161501.65890.22
P407
P577
2005-06-01T00:00:00Z